Company news

Ipsen SA news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

DETERA Therapeutics Wins the Ipsen Golden Ticket 2025

October 15, 2025

Ipsen - September 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

October 7, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 39 - 2025

September 30, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 38 - 2025

September 23, 2025

Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III

September 22, 2025

Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC

September 19, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 37 - 2025

September 16, 2025

Ipsen - August 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

September 11, 2025

Health Canada Approves Bylvay™ (odevixibat) for the treatment of cholestatic pruritus in patients with Alagille Syndrome

September 9, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 35 - 2025

September 2, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 34 - 2025

August 29, 2025

Ipsen - July 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

August 27, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 33 - 2025

August 19, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2025

August 12, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2025

August 5, 2025

Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance

July 31, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2025

July 29, 2025

Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors

July 24, 2025

Ipsen announces changes to its Executive Committee

July 23, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2025

July 22, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2025

July 16, 2025

Ipsen - June 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

July 10, 2025

The Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal and IRICoR Announce initiation of Phase 1 Trial of Licensed Small Molecule Therapy for Solid Tumors

July 8, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2025

July 1, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2025

June 24, 2025

Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors

June 20, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2025

June 17, 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2025

June 13, 2025

Ipsen - May 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

June 12, 2025

Ipsen S.A. - Initiation of the share buy-back program

June 2, 2025

Ipsen S.A. - Annual General Meeting held on 21 May 2025

May 21, 2025

Ipsen - April 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

May 12, 2025

Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary cholangitis

May 7, 2025

Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation

May 6, 2025

Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2025 Annual General Meeting

April 30, 2025

← Newer news releases

Calls

The 5 newest of 7 calls. Every call is listed under its year.

Decks

The 5 newest of 90 decks. Every deck is listed under its year.